Thermo Fisher hails PPD’s wins of ‘very large’ customers following merger

By Nick Taylor

- Last updated on GMT

© Choreograph / Getty Images
© Choreograph / Getty Images

Related tags Thermo fisher scientific M&A Ppd

Thermo Fisher Scientific’s clinical service unit PPD has won some “very large” customers since becoming part of the broader group in a mega-merger, according to CEO Marc Casper.

In December, Thermo Fisher closed its largest deal to date, paying $17.4bn to acquire contract research organization PPD. Evidence that the combined company was off to a fast start emerged in July, when Thermo Fisher increased its PPD revenue forecast for 2022 to $6.8bn.

Casper, the CEO of Thermo Fisher, provided more details on why PPD is outperforming expectations at the Morgan Stanley 20th Annual Global Healthcare Conference, explaining how the clinical research unit is benefiting from being part of the broader business.

When I think about the early days of the acquisition, customers that have been long-standing Thermo Fisher Scientific customers, that might have used PPD in a more sparing way, have given us the opportunity to work with them. So, we’ve won a meaningful number of new customers, some very large ones. And now it’s our job to really exceed expectations​,” said Casper.

Thermo Fisher raised its synergy forecast for the PPD merger six months after closing the takeover. The updated outlook added $100m to the revenue synergy in year three, bringing the total up to $250m, and raised the cost synergy from $25m to $100m.

Casper used the investor conference to shed light on the early synergies that the team has identified, zeroing in on an interface between PPD’s clinical trials and the broader business as a notable win so far.

The first real synergy area that’s been exciting ... has been in our clinical trials packaging business, where we’re effectively securing the drug supply and packaging and labeling it, securing comparative drugs, things of that sort, blinding them. We’ve had a number of wins where effectively it’s enabling the physical aspect of a clinical trial in addition to all of the paperwork and all the administration of the clinical trials​,” said Casper.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

Related suppliers

Follow us


View more